Clincosm LogoSign in Get a demo

glycogen storage disease type ii

Showing 1 - 22 of 22
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Pompe Disease, Muscle Loss, Obesity Trial (Multi-ingredient supplement (PDT-MIS), Placebo (PLA))

Not yet recruiting
  • Pompe Disease
  • +7 more
  • Multi-ingredient supplement (PDT-MIS)
  • Placebo (PLA)
  • (no location specified)
Nov 8, 2023

Glycogen Storage Disease Type II, Pompe Disease (Late-onset) Trial in Milan (Inspiratory Muscle Training (IMT), Inspiratory

Recruiting
  • Glycogen Storage Disease Type II
  • Pompe Disease (Late-onset)
  • Inspiratory Muscle Training (IMT)
  • Inspiratory Muscle Training (IMT) + Air Stacking
  • Milan, Italy
    IRCCS S. Maria Nascente - Fondazione Don Carlo Gnocchi
Jul 11, 2023

Glycogen Storage Disease Type II Trial in Worldwide (Alglucosidase alfa GZ419829)

Recruiting
  • Glycogen Storage Disease Type II
  • Alglucosidase alfa GZ419829
  • Leuven, Belgium
  • +8 more
Jan 17, 2023

Glycogen Storage Disease Type II, Pompe Disease Trial in Worldwide

Recruiting
  • Glycogen Storage Disease Type II
  • Pompe Disease
    • Birmingham, Alabama
    • +274 more
    Jan 12, 2023

    Pompe Disease, Pompe Disease (Late-onset), Glycogen Storage Disease Type 2 Trial in Worldwide (SPK-3006)

    Active, not recruiting
    • Pompe Disease
    • +6 more
    • SPK-3006
    • Phoenix, Arizona
    • +28 more
    Jul 22, 2022

    Glycogen Storage Disease Type II Trial in France (Avalglucosidase alfa (GZ402666))

    Recruiting
    • Glycogen Storage Disease Type II
    • Avalglucosidase alfa (GZ402666)
    • Brest, France
    • +9 more
    Jul 22, 2022

    Glycogen Storage Disease Type II Trial in Worldwide (avalglucosidase alfa)

    Recruiting
    • Glycogen Storage Disease Type II
    • avalglucosidase alfa
    • Leuven, Belgium
    • +7 more
    Jul 13, 2022

    Higher Dose of Alglucosidase Alpha for Pompe Disease

    Not yet recruiting
    • Glycogen Storage Disease Type II
    • Alglucosidase Alfa
    • (no location specified)
    Aug 17, 2021

    Pompe Disease, Glycogen Storage Disease Type II, Lysosomal Storage Diseases Trial in Gainesville (Diet and Exercise)

    Completed
    • Pompe Disease
    • +2 more
    • Diet and Exercise
    • Gainesville, Florida
      University of Florida Clinical Research Center
    May 13, 2021

    Biomarker for Glycogen Storage Diseases (BioGlycogen)

    Active, not recruiting
    • Fructose Metabolism, Inborn Errors
    • +9 more
      • Rostock, Germany
      • +3 more
      May 12, 2021

      Metabolism, Inborn Errors, Lipid Metabolism, Inborn Errors, Carbohydrate Metabolism, Inborn Errors Trial in Copenhagen (Sugar)

      Unknown status
      • Metabolism, Inborn Errors
      • +22 more
      • Sugar
      • Copenhagen, Denmark
        Neuromuscular Research Unit, 3342
      Oct 15, 2019

      Glycogen Storage Disease Type II Trial in Durham (RMT therapy using modified RMT device, Sham-RMT therapy using modified RMT

      Completed
      • Glycogen Storage Disease Type II
      • RMT therapy using modified RMT device
      • Sham-RMT therapy using modified RMT device
      • Durham, North Carolina
        Duke University Medical Center
      Jul 29, 2019

      Motor Development, Motor Function and Electrophysiologic

      Unknown status
      • Glycogen Storage Disease Type II
      • observation study
      • Taipei, Taiwan
        Taipei Veteran General Hospital : Taipei City, Taiwan 11217, R.O
      May 2, 2016

      Glycogen Storage Disease Type II Trial in New York (High Protein and Exercise Therapy along-with Nocturnal Enteral Feeding)

      Withdrawn
      • Glycogen Storage Disease Type II
      • High Protein and Exercise Therapy along-with Nocturnal Enteral Feeding
      • New York, New York
        Columbia University Medical Center
      Apr 9, 2015

      Pompe Disease, Glycogen Storage Disease Type II, Acid Maltase Deficiency Disease Trial in Durham (recombinant human acid

      Completed
      • Pompe Disease
      • +3 more
      • recombinant human acid alpha-glucosidase (rhGAA)
      • Durham, North Carolina
        Duke University Medical Center
      Nov 12, 2014

      Pompe Disease, Glycogen Storage Disease Type II Trial in Louisville, Durham (Alglucosidase Alfa, Methotrexate, Rituximab)

      Completed
      Has Results
      • Pompe Disease
      • Glycogen Storage Disease Type II
      • Alglucosidase Alfa
      • +2 more
      • Louisville, Kentucky
      • +1 more
      Apr 9, 2014

      Pompe Disease Infantile-Onset, Glycogen Storage Disease Type II Trial in France, South Africa, United States (Myozyme)

      Completed
      • Pompe Disease Infantile-Onset
      • Glycogen Storage Disease Type II
      • Myozyme
      • Oakland, California
      • +7 more
      Feb 4, 2014

      Glycogen Storage Disease Type II, Pompe Disease, Acid Maltase Deficiency Disease Trial in New Brunswick (Alglucosidase alfa)

      Completed
      • Glycogen Storage Disease Type II
      • +3 more
      • Alglucosidase alfa
      • New Brunswick, New Jersey
        Saint Peter's University Hospital
      Feb 4, 2014

      Glycogen Storage Disease Type II, Pompe Disease, Acid Maltase Deficiency Disease Trial in Worldwide (Myozyme)

      Completed
      • Glycogen Storage Disease Type II
      • +3 more
      • Myozyme
      • Gainesville, Florida
      • +5 more
      Feb 4, 2014

      Glycogen Storage Disease Type II Trial in Worldwide (Myozyme)

      Completed
      • Glycogen Storage Disease Type II
      • Myozyme
      • Gainesville, Florida
      • +7 more
      Feb 4, 2014

      Effects of Pharmacological Chaperones in Cells From Pompe

      Completed
      • Pompe Disease
      • Glycogen Storage Disease Type II
      • Observation
      • Gainesville, Florida
      • +3 more
      Jun 4, 2008

      Genetic and Family Studies of Inherited Muscle Diseases

      Completed
      • Dermatomyositis
      • +4 more
        • Bethesda, Maryland
          National Institute of Arthritis and Musculoskeletal and Skin Dis
        Mar 4, 2008